SunP Biotech
Develops 3D bioprinting systems and bioinks for tissue engineering and drug testing using a patented screw-based extrusion technique.
- CEO / Founder
- Wei Sun
- Team Size
- 11-50
- Stage
- Commercial
- Total Funding
- $4.3M
- Latest Round
- Venture Round
- Key Investors
- Orca M&A Capital
Technology & Products
Key Products
ALPHA-CPD1; Bioinks; Custom tissue products
Technological Advantage
Proprietary screw-based extrusion avoids pneumatic heavy equipment, enabling a more compact and standardized bioprinting workflow.
Differentiation
Value Proposition
Reduces equipment footprint and complexity by replacing pneumatic systems with a patented screw-based extrusion process, ensuring high precision and sterility for tissue engineering.
How They Differentiate
Uses screw-based extrusion instead of pneumatic systems, offering higher precision and a more compact form factor than traditional bioprinters.
Market & Competition
Target Customers
Scientific research labs, higher education, pharmaceutical research
Industry Verticals
Tissue engineering; Drug testing; Organ-on-a-chip; Cancer study
Competitors
CELLINK; RegenHU; Alleviate
Growth & Milestones
Growth Metrics
Estimated annual revenue of $4.7M; Total funding raised $4.3M; 400+ LinkedIn followers; 2 global locations (USA and China)
Major Milestones
ALPHA-CPD1 bioprinter won Silver A’s Design Award 2017-2018
Notable Customers
Columbia University; Tsinghua University